The study also linked improved microbiota diversity to better liver function.

Més de 500 persones animades per veïns i veïnes del barri han participat en la cursa ha estat el primer dels esdeveniments que s’han organitzat per celebrar els 30 anys del Vall d’Hebron Institut de Recerca

These results reinforce the need for more individualized attention to address educational needs from an early stage.

This new technology will be completely harmless for patients, as it does not use radiation, and will offer superior image quality and better monitoring of tumours, among other benefits.

"Generation of a bank of surgical orthotopic PDX (patient-derived xenografts) models within the framework of a personalized medicine program in pediatric cancer" was the awarded work, of the Childhood Cancer and Hematological Diseases Group of VHIR.

The work led by Dr. Regis demonstrates that performing robotic reconstruction after radical prostatectomy is associated with better urinary control.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

A study, co-led by Vall d’Hebron, has analysed the evolution of clinical trials with children and adolescents with cancer over the last 15 years, with the aim of optimising efficacy and defining lines for further progress.

The Biomedical Research in Cancer Stem Cells group at VHIR has identified a new therapeutic target and is working to find new therapies for this type of tumor.

Researchers at the VHIR have carried out a study showing that the ClC-5 protein regulates collagen levels through the β-catenin pathway and lysosomal degradation.

VHIR organises the first meeting between entrepreneurs and the investment ecosystem.

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

The event, organized by Vall d'Hebron and Eurecat, has brought together health professionals and researchers in clinically applied AI to improve the medical care of patients.

Vall d'Hebron presents positive results from two studies in transfusion-dependent thalassaemia and severe bone marrow aplasia at the EBMT Annual Meeting on haematopoietic stem cell transplantation.

The study, in which Vall d'Hebron participates, helps to understand the variability among patients with retinitis pigmentosa.

For two days, communication professionals from health and research institutions, experts in the field of health communication and specialized journalists from around the world will meet to debate the key issues of the present and the future.

The new protocol has the same efficacy as the standard one, but only a quarter of the duration, reducing dropout rates and side effects.

The research will perform a functional analysis of phenotype-modifying genetic variants in patients affected by familial hypomagnesaemia with hypercalciuria and nephrocalcinosis (HFHNC).

Vall d'Hebron has participated in a phase III clinical trial which confirmed the efficacy and safety of subcutaneous infusion of levodopa therapy.

This initiative is part of a pioneering study that seeks to assess how the relationship between different age groups can influence the quality of life and mental health of patients.

A clinical trial with the prototype of the device shows that the use of this technology improves patient monitoring by nurses and reduces post-surgical complications.

The TOUCH MSCA-COFUND doctoral training programme, led by UAB and focusing on the field of mental health, has opened its first call for applications, offering 13 doctoral positions.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.